搜索优化
English
全部
搜索
图片
视频
地图
资讯
Copilot
更多
购物
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
最佳匹配
最新
资讯
生物通
26 天
基于细胞周期和免疫特征预测转移性HR+/HER2-乳腺癌对 ...
Roswell Park综合癌症中心的研究团队开展了一项"真实世界"临床研究,通过多组学方法揭示了预测CDK4/6i疗效的关键生物标志物。 该研究纳入了155例接受CDK4/6i治疗的转移性HR+/HER2-乳腺癌患者,根据无进展生存期 (PFS)分为极端响应组 (PFS<6个月)和长期响应组 (PFS>23个月)。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Abbott: 160+ still missing
How to help TX flood victims
Family members swept away
Clears way for mass firings
Italy outraged at killing
Greece shuts Acropolis
Milan airport tragedy
Discharged from hospital
Says churches can endorse
TSA to end shoes-off policy
4 killed in NC plane crash
Ship attacked in Red Sea
ICE facility attack arrests
Judge: Case should proceed
Judge blocks defunding plan
Marseille flights suspended
Osborn launches Senate bid
5 Israeli soldiers killed
ICC issues arrest warrants
Appoints new CEO
Linqto files for bankruptcy
UK Post Office scandal
50% tariff on copper imports
Rubio impersonator used AI
Wins malaria drug approval
Sentencing set for October 3
Warns of new tariff hikes
WI conversion therapy ruling
Reveals new book club pick
Files for 'blue chip' ETF
Jones enters governor's race
King Charles hosts Macron
Retires from NHL
反馈